National Institutes of Health to Grant Exclusive License for LCAT Technology to Reduce Cholesterol Accumulation

Summary

The National Institutes of Health is considering granting an exclusive license to AlphaCore Pharma, Inc. for the use of Lecithin-Cholesterol Acyltransferase (LCAT) technology to treat cardiovascular and nephropathy conditions, with the potential for global use.